The Rx Recap: March 16-22

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

Study highlights how PCOS alters uterine lining

A recent study covered by Contemporary OBGYN revealed significant differences in uterine lining composition between women with polycystic ovary syndrome (PCOS) and those without the condition. Researchers developed a detailed cell map of endometrial tissue, identifying disrupted gene expression in PCOS patients, which may contribute to fertility challenges, miscarriage risk, and increased susceptibility to endometrial cancer. The study analyzed tissue samples from 12 women with PCOS and 5 healthy controls, assessing hormone levels, ovarian function, and endometrial cell types. Findings showed an increased proportion of epithelial cells and fewer stromal and lymphoid cells in PCOS patients, with little change after intervention. Metformin treatment helped regulate some hormonal imbalances and partially restored estrogen-α expression in certain epithelial subpopulations.

Unmasking Long COVID: Dr Noah Greenspan on Recovery, Research Gaps, and the Future of Treatment

In an interview with Infection Control Today, Noah Greenspan, DPT, PT, CCS, EMT-B, discusses the challenges of Long COVID (LC) and the ongoing need for research and recognition. A specialist in cardiopulmonary rehabilitation, Greenspan highlights LC’s overlap with post-viral syndromes like ME/CFS and the lack of standardized diagnostic criteria. He emphasizes careful activity management, hydration, compression garments, and oxygen therapy as key strategies for symptom relief. While research has improved awareness, major gaps remain in funding and acceptance. Greenspan stresses the importance of patient advocacy and continued medical focus to address LC’s long-term impact.

Advocates for those with Down syndrome dread prospect of Medicaid cuts

In an interview with Chief Healthcare Executive, Heather Sachs of the National Down Syndrome Congress warns of the potential impact of Medicaid cuts on individuals with Down syndrome. With Congress considering major reductions in Medicaid funding, Sachs calls it a “5-alarm fire,” stressing that cuts could limit access to essential healthcare, home and community-based services, and school programs. She also raises concerns about proposed Medicaid work requirements, which could lead to millions losing coverage. Sachs urges continued advocacy, emphasizing that past efforts have successfully protected health care access. “We have to keep fighting,” she says.

Q&A: Knowledge is Key for Adapting AI within Pharmacy Practice

In an interview with Drug Topics, Don Roosan, PharmD, PhD, emphasizes the transformative potential of AI in pharmacy. He believes AI, including large-language models like ChatGPT, will revolutionize the field, making processes more efficient and empowering pharmacists to make informed decisions. While concerns exist, Roosan stresses that “knowledge is power” and encourages pharmacists to understand AI’s capabilities and biases. He highlights the importance of education in overcoming fear, noting that AI will create new opportunities rather than just replace jobs. “This is just the beginning,” Roosan says, urging pharmacists to embrace AI for better patient care.

The First Optimized Self-Replicating RNA (srRNA) Technology

In BioPharm International's inaugural Pivotal Paper series, experts discuss groundbreaking advances in self-replicating RNA (srRNA) vaccine technology. The featured study, published in Springer Nature, highlights srRNA’s superior bioactivity, dose-sparing potential, and durable immune response compared to traditional mRNA vaccines. Panelists, including industry leaders Philip Dormitzer, PhD, and Andy Geall, PhD, emphasize the technology's scalability and potential for single-dose vaccines. The study demonstrated the safety and immunogenicity of an optimized srRNA rabies vaccine in humans, opening pathways for broader applications in infectious diseases, cancer vaccines, and protein replacement therapies.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.